童年创伤对抑郁情绪的影响:有调节的中介模型

 目的 为明确童年期创伤经历对抑郁情绪的作用机制,本研究构建了一个有调节的中介模型,考察在新兵中愤怒表达在二者关系中的中介作用以及压力的调节作用。方法 418 名男性新兵为被试,采用问卷法对童年期创伤经历、压力、愤怒表达及抑郁情绪进行调查。结果 (1)在控制年龄、学历、家庭所在地、是否独生和父母关系后,童年创伤对抑郁情绪具有显著的正向预测作用;(2)愤怒对内表达、愤怒对外表达和控制愤怒对外表达能够在童年创伤经历与抑郁情绪的关系中起中介作用;(3)童年创伤经历对抑郁情绪的直接预测作用受到压力的调节。结论 引导新兵合理地表达愤怒情绪,对其抑郁情绪及其心理社会适应服务具有意义。     

颅内动脉瘤支架植入术后新生内膜增生临床研究

【摘要】 目的 探讨颅内动脉瘤支架植入术后新生内膜增生（NIH）变化及其影响因素。方法 收集2018年10月至2020年10月在昆明医科大学第一附属医院接受支架辅助弹簧圈栓塞（SACE）或血流导向装置（FD）治疗的42例颅内前循环动脉瘤患者临床资料。分析治疗后支架NIH状况及影响因素。两名高年资神经介入医师根据血管造影图像,测量并记录患者术后即刻、术后随访复查时支架段最狭窄处、颈内动脉岩段直径,并计算每幅图像比率（T值,支架段直径/岩段颈内动脉直径）。 结果 T值变化呈由大至小再由小变大的动态过程,远期随访10～15个月（中位12.5个月）T值已基本恢复至术后即刻水平。单因素分析结果显示年龄、动脉瘤长径是患者中期NIH的影响因素。多因素logistic回归分析显示年龄是中期NIH发生的预测因子（OR=0.903,95%CI=0.828～0.984,P=0.020）,患者年龄越大治疗后出现NIH的可能性越小。结论 颅内动脉瘤支架植入术后NIH变化是一逐渐加重、逐渐减轻的动态过程,远期随访时支架段血管直径基本恢复至术后即刻水平。年龄、动脉瘤大小是患者中期NIH影响因素,年龄是独立保护因素。     

165例儿童腹水的病因分析北大核心CSCD

目的 分析儿童腹水的病因及临床特点,为儿童腹水的诊治提供理论依据,减少漏诊、误诊。方法 回顾性分析2010年1月1日至2019年12月31日间住院诊断腹水患儿的临床特征。结果 165例腹水儿童,男女比例1.53∶1,平均发病年龄(6±4)岁。腹水病因依次为:外科急腹症(39例,23.6%)、感染性疾病(39例,23.6%)、肿瘤性疾病(27例,16.4%)、肝源性疾病(18例,10.9%)、胰腺炎(10例,6.1%)、心源性疾病(8例,4.8%)、风湿免疫性疾病(6例,3.6%)、肾源性疾病(5例,3.0%)等。按发病年龄分为婴儿33例,幼儿24例,学龄前期30例,学龄期41例,青春期37例。外科急腹症、肝源性疾病是引起婴儿组腹水的主要原因(P<0.05),幼儿组的首要病因是肿瘤性疾病(P<0.05),青春期组的首要病因为感染性疾病(P<0.05)。结论 外科急腹症、感染性疾病、肿瘤性疾病、肝源性疾病是儿童腹水的常见病因;不同年龄段儿童腹水的主要病因存在一定差异。     

基质金属蛋白酶/组织金属蛋白酶抑制物表达失衡在大鼠肾脏衰老过程中的意义

目的:探讨基质金属蛋白酶(MMPs)及其抑制物(TIMPs)在大鼠肾脏衰老过程中的作用。方法:选用3、12和24月龄大鼠，采用免疫组化技术分别检测基质金属蛋白酶—2、9(MMP—2、9)、组织金属蛋白酶抑制物—1、2(TIMP—1、2)、转化生长因子—β1(TGF—β1)等在不同月龄大鼠肾组织中的表达。结果TIMP—1、TIMP—2及TGF—β1主要表达在肾小球、肾小管、间质及血管，并随增龄表达增强(P＜O．01)；MMP—9、MMP—2主要表达在肾小管上皮细胞，随增龄表达无变化；TIMP—1与TGF—β1与肾小球硬化面积有相关性(r分别为O．751、O．771，P＜O．05)；TIMP—1与TIMP—2与小管间质纤维化面积有相关性(r分别为O．783、O．766，P＜O．O5)。结论:MMPs／TIMPs表达失衡在肾脏衰老过程中可能起重要作用。     

Experimental reconstruction of dog's esophagus with biotype artificial esophagus

OBJECTIVE: At present, there are few materials available for esophagus reconstruction anywhere in the world. The reported survival rate in animals during the perioperative period is comparatively low. The present study assessed the feasibility of using a biotype artificial esophagus in the reconstruction of a dog's esophagus. METHODS: In 30 mongrel dogs, a portion of the thoracic esophagus was resected and an 8 cm section of artificial esophagus was transplanted to reconstruct the organ. The survival rate, food intake and process of healing were observed. RESULTS: Of the 30 dogs, 28 survived the peri­operative period (93.3% survival). Two dogs (6.7%) developed an anastomotic fistula; 19 dogs survived for 1 year, a survival rate of 79.2% (19/24) with the remaining six dogs were killed according to the experimental protocol. Detachment of the artificial esophagus occurred on average 28.8 days after operation and the dogs suffered from varying degrees of dysphagia 23?45 days after operation. Gradual remission occurred after 4 months. The histological study revealed that the regenerated esophagus was composed of fibrous and connective tissues and the luminal surface was covered with squamous epithelium in 3?6 months. CONCLUSION: The transplanted artificial esophagus detached after the surrounding ‘regenerated esophagus’ had formed, and the squamous epithelium gradually covered the luminal surface. Continuous remodeling of the ‘regenerated esophagus’ gradually relieved the stenosis. Whether detachment of the implant and the postoperative stenosis can be solved is the key problem restricting the use of the biotype artificial esophagus in clinical practice.     

鸟-胞内分枝杆菌复合群鸟和胞内分枝杆菌亚种对20种药物的敏感性特征及亚种间药物敏感性比较

目的 分析鸟-胞内分枝杆菌复合群鸟分枝杆菌亚种和胞内分枝杆菌亚种对20种药物的敏感性特征及比较2个亚种间的药物敏感性差异。方法 用微孔板Alamar blue显色法分别检测97株鸟分枝杆菌和172株胞内分枝杆菌对克拉霉素、卷曲霉素和利福布丁等20种药物的最小抑菌浓度,判断其敏感性,分析2个亚种菌株对20种药物的敏感性特征以及对利福霉素类、氨基糖苷类和大环内酯类内药物的交叉耐药性,并比较2个亚种对20种药物的敏感性差异。结果 对鸟分枝杆菌敏感率高于80%的药物依次是卷曲霉素(100%,97/97)、阿米卡星(97.9%,95/97)、利福布丁(96.9%,94/97)、利福平和卡那霉素(83.5%,81/97)及克拉霉素(82.5%,80/97);对胞内分枝杆菌敏感率高于80%的药物依次是阿米卡星(99.4%,171/172)、卡那霉素(95.9%,165/172)、利福布丁(95.4%,164/172)、克拉霉素(94.2%,162/172)、氯法齐明(87.2%,150/172)、卷曲霉素和罗红霉素(86.1%,148/172)及利福喷丁(82.6%,142/172)。97株鸟分枝杆菌分别有1株、1株和17株而172株胞内分枝杆菌中分别有0株、7株和6株同时对氨基糖苷类、利福霉素类和大环内酯类内各种药物同时耐药或中度敏感。鸟分枝杆菌对利福平和卷曲霉素的敏感率明显高于胞内分枝杆菌。胞内分枝杆菌对利福喷丁、妥布霉素、卡那霉素、乙胺丁醇、莫西沙星、克拉霉素、阿奇霉素和罗红霉素的敏感率均高于鸟分枝杆菌。结论 鸟和胞内分枝杆菌均对卷曲霉素、阿米卡星、利福布丁和克拉霉素敏感性较高,对胞内分枝杆菌敏感的药物多于鸟分枝杆菌,利福喷丁仅对胞内分枝杆菌抗菌性较好,而利福平仅对鸟分枝杆菌抗菌性较好,乙胺丁醇对两个亚种敏感性均较差;对同一种类的药物做药物敏感性试验可为临床医生治疗鸟或胞内分枝杆菌感染选择合适的替代药物做依据。     

血清转化生长因子β1检测对血吸虫病肝纤维化的诊断和疗效评估的价值

转化生长因子β1(TGFβ1)是肝纤维化形成过程中重要的细胞因子之一。TGFβ1主要存在于炎症和纤维化部位，在不同肝病患者肝脏中的表达均显著增高^[1]。由于肝活检具有一定的创伤性，不利于动态观察和疗效考核，陈峰等^[2]曾应用RT-PCR和dot blot法检测外周血单个核细胞(PBMC)中TGF β1 mRNA，并认为PBMC中TGF β1 mRNA水平与肝纤维化的     

Determination of High Mobility Group A1 (HMGA1) Expression in Hepatocellular Carcinoma: A Potential Prognostic Marker

Our objective was to investigate the expression of HMGA1 mRNA and protein in hepatocellular carcinoma (HCC) and the correlation between its expression and clinical pathological characteristics and prognosis. HMGA1 expression was determined at both the mRNA level and the protein level in 30 HCC tissues and their corresponding paracancer liver tissues (PCLTs) and 2 normal liver tissues by RT-PCR and IHC. Follow-up study was done on the 30 patients involved in this research. HMGA1 mRNA was detected in nine cases of HCC tissues and two PCLTs, for a positivity rate of 30% and 6.7%, respectively (P < 0.05), whereas no HMGA1 mRNA expression was found in normal liver tisssues. Clinicopathological analysis revealed that HMGA1 mRNA expression was significantly correlated with Edmondson's grade (P < 0.05). HMGA1 protein was detected in four HCC tissues by IHC and located mainly in the nuclei; no positive staining was found in PCLTs. Follow-up study showed that HMGA1 mRNA-positive patients had a higher risk of recurrence/metastasis and a shorter survival than negative cases (P < 0.05). Our findings indicate that HMGA1 may be involved in the carcinogenesis and invasiveness of HCC and the determination of HMGA1 can be of great value in predicting the prognosis of patients with HCC. This work was supported in part by National Key Technologies R&D Program Grant 2001BA703B04 and National Basic Research Program Grant 2004CB720303, Ministry of Science and Technology, People's Republic of China.     

Brk is coamplified with ErbB2 to promote proliferation in breast cancer

Amplification of the receptor tyrosine kinase ErbB2 is frequently observed in breast cancer. Amplification of erbB2 is also associated with multiple genomic gains and losses; however, the importance of these associated changes is largely unknown. We demonstrate that Brk, a cytoplasmic tyrosine kinase, is coamplified and coexpressed with ErbB2 in human breast cancers. ErbB2 interacts with Brk and increases its intrinsic kinase activity. Expression of Brk enhances the ErbB2-induced activation of Ras/MAPK signaling and cyclin E/cdk2 activity to induce cell proliferation of mammary 3-dimensional acini in culture. In a murine model of breast cancer, expression of Brk was found to shorten the latency of ErbB2-induced tumors by promoting cell proliferation, with no effect on protection from apoptosis. Furthermore, overexpression of Brk conferred resistance to the ability of Lapatinib, an ErbB2 kinase inhibitor, to inhibit ErbB2-induced proliferation. Thus, we identified Brk as a drug target for ErbB2-positive cancers.